Johnson & Johnson $JNJ Shares Purchased by Ethos Financial Group LLC

Key Points

• Ethos Financial Group LLC increased its holdings in Johnson & Johnson by 213.4% in Q1, now owning 17,984 shares valued at approximately $2.74 million.
• Johnson & Johnson's stock price opened at $176.76 and has seen a 12-month range of $140.68 to $177.27.
• The company recently declared a $1.30 quarterly dividend, representing a 2.9% yield and a payout ratio of 55.61%.

Ethos Financial Group LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 213.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,984 shares of the company's stock after buying an additional 12,245 shares during the period. Ethos Financial Group LLC's holdings in Johnson & Johnson were worth $2,743,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. LeConte Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth about $467,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Johnson & Johnson by 9.4% during the first quarter. Steward Partners Investment Advisory LLC now owns 361,775 shares of the company's stock worth $59,997,000 after purchasing an additional 31,232 shares during the last quarter. Raymond James Financial Inc. grew its holdings in shares of Johnson & Johnson by 2.2% during the first quarter. Raymond James Financial Inc. now owns 9,468,114 shares of the company's stock worth $1,570,192,000 after purchasing an additional 203,291 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its holdings in shares of Johnson & Johnson by 32.1% during the first quarter. Alliance Wealth Advisors LLC UT now owns 10,151 shares of the company's stock worth $1,683,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Forvis Mazars Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 37.6% during the first quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company's stock worth $9,728,000 after purchasing an additional 16,019 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.38 during mid-day trading on Monday, reaching $176.26. The stock had a trading volume of 9,283,816 shares, compared to its average volume of 8,411,460. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $424.49 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $177.57. The business has a 50 day simple moving average of $161.70 and a 200 day simple moving average of $158.60.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.